11 results on '"Giorgia Cioccoloni"'
Search Results
2. Ergothioneine supplementation in people with metabolic syndrome (ErgMS): protocol for a randomised, double-blind, placebo-controlled pilot study
- Author
-
Xiaoying Tian, Giorgia Cioccoloni, Joanna H. Sier, Khalid M. Naseem, James L. Thorne, and J. Bernadette Moore
- Subjects
Ergothioneine ,Metabolic syndrome ,Supplementation ,Metabolome ,Oxidative stress ,Inflammation ,Medicine (General) ,R5-920 - Abstract
Abstract Background Ergothioneine is a naturally occurring metabolite of histidine found in many foods and in high amounts in mushrooms. In vivo, ergothioneine acts as an antioxidant and is widely distributed in most mammalian tissues. While ergothioneine is sold as a dietary supplement for its antioxidant and anti-inflammatory properties, to date there are no published intervention trials examining its health benefits in humans. The aim of this work was to develop a study protocol for a pilot interventional trial that will establish the primary and secondary outcomes, and the power required, for a definitive randomised controlled trial to test the hypothesis that ergothioneine supplementation is beneficial for people with metabolic syndrome. Methods We have designed the ErgMS study as a single-centre, randomised, double-blind, placebo-controlled, 3-arm parallel, pilot intervention trial, which aims to supplement participants with either placebo, 5 or 30 mg/day ergothioneine for 12 weeks. Measurements of metabolic syndrome risk factors, serum markers of oxidative stress (lipid peroxidation), inflammation, blood platelet function and liver function will take place at baseline, and after 6 weeks and 12 weeks of supplementation. In addition, we will examine if there are any changes in the serum metabolome in response to ergothioneine supplementation. Linear regression and two-way ANOVA will be utilised to analyse the association between ergothioneine and measured variables. Discussion The ErgMS study will be the first study to address the question does ergothioneine supplementation have health benefits for people with metabolic syndrome. Study results will provide preliminary data as to which dose may improve inflammatory markers in adults with metabolic syndrome and will inform dose and primary outcome selection for a definitive randomised controlled trial. Trial registration ISRCTN, ISRCTN25890011 Registered February 10th, 2021
- Published
- 2021
- Full Text
- View/download PDF
3. Influence of FTO rs9939609 and Mediterranean diet on body composition and weight loss: a randomized clinical trial
- Author
-
Laura Di Renzo, Giorgia Cioccoloni, Simone Falco, Ludovico Abenavoli, Alessandra Moia, Paola Sinibaldi Salimei, and Antonino De Lorenzo
- Subjects
Nutrigenetics ,FTO ,Mediterranean diet ,Body composition ,Medicine - Abstract
Abstract Background The Mediterranean diet (MeD) plays a key role in the prevention of obesity. Among the genes involved in obesity, the Fat mass and obesity-associated gene (FTO) is one of the most known, but its interaction with MeD remained uncertain so far. Methods We carried out a study on a sample of 188 Italian subjects, analyzing their FTO rs9939609 alleles, and the difference in body composition between the baseline and a 4-weeks nutritional intervention. The sample was divided into two groups: the control group of 49 subjects, and the MeD group of 139 subjects. Results We found significant relations between MeD and both variation of total body fat (ΔTBFat) (p = 0.00) and gynoid body fat (p = 0.04). ∆TBFat (kg) demonstrated to have a significant relation with the interaction diet-gene (p = 0.04), whereas FTO was associated with the variation of total body water (p = 0.02). Conclusions MeD demonstrated to be a good nutritional treatment to reduce the body fat mass, whereas data about FTO remain uncertain. Confirming or rejecting the hypothesis of FTO and its influence on body tissues during nutritional treatments is fundamental to decide whether its effect has to be taken into consideration during both development of dietetic plans and patients monitoring. Trial Registration ClinicalTrials.gov Id: NCT01890070. Registered 01 July 2013, https://clinicaltrials.gov/ct2/show/NCT01890070
- Published
- 2018
- Full Text
- View/download PDF
4. Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?
- Author
-
Ornella Franzese, Francesco Torino, Elisa Giannetti, Giorgia Cioccoloni, Angelo Aquino, Isabella Faraoni, Maria Pia Fuggetta, Liana De Vecchis, Anna Giuliani, Bernd Kaina, and Enzo Bonmassar
- Subjects
abscopal effect ,xenogenization ,alkylating agents ,dacarbazine ,temozolomide ,immune response ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The current state of cancer treatment is still far from being satisfactory considering the strong impairment of patients’ quality of life and the high lethality of malignant diseases. Therefore, it is critical for innovative approaches to be tested in the near future. In view of the crucial role that is played by tumor immunity, the present review provides essential information on the immune-mediated effects potentially generated by the interplay between ionizing radiation and cytotoxic antitumor agents when interacting with target malignant cells. Therefore, the radiation-dependent abscopal effect (i.e., a biological effect of ionizing radiation that occurs outside the irradiated field), the influence of cancer chemotherapy on the antigenic pattern of target neoplastic cells, and the immunogenic cell death (ICD) caused by anticancer agents are the main topics of this presentation. It is widely accepted that tumor immunity plays a fundamental role in generating an abscopal effect and that anticancer drugs can profoundly influence not only the host immune responses, but also the immunogenic pattern of malignant cells. Remarkably, several anticancer drugs impact both the abscopal effect and ICD. In addition, certain classes of anticancer agents are able to amplify already expressed tumor-associated antigens (TAA). More importantly, other drugs, especially triazenes, induce the appearance of new tumor neoantigens (TNA), a phenomenon that we termed drug-induced xenogenization (DIX). The adoption of the abscopal effect is proposed as a potential therapeutic modality when properly applied concomitantly with drug-induced increase in tumor cell immunogenicity and ICD. Although little to no preclinical or clinical studies are presently available on this subject, we discuss this issue in terms of potential mechanisms and therapeutic benefits. Upcoming investigations are aimed at evaluating how chemical anticancer drugs, radiation, and immunotherapies are interacting and cooperate in evoking the abscopal effect, tumor xenogenization and ICD, paving the way for new and possibly successful approaches in cancer therapy.
- Published
- 2021
- Full Text
- View/download PDF
5. Can psychobiotics intake modulate psychological profile and body composition of women affected by normal weight obese syndrome and obesity? A double blind randomized clinical trial
- Author
-
Antonino De Lorenzo, Micaela Costacurta, Giuseppe Merra, Paola Gualtieri, Giorgia Cioccoloni, Massimiliano Marchetti, Dimitrios Varvaras, Raffaella Docimo, and Laura Di Renzo
- Subjects
NWO syndrome ,Probiotic ,Psychobiotic ,Psychological profile ,Body composition ,Medicine - Abstract
Abstract Background Evidence of probiotics effects on gut function, brain activity and emotional behaviour were provided. Probiotics can have dramatic effects on behaviour through the microbiome–gut–brain axis, through vagus nerve. We investigated whether chronic probiotic intake could modulate psychological state, eating behaviour and body composition of normal weight obese (NWO) and preobese–obese (PreOB/OB) compared to normal weight lean women (NWL). Methods 60 women were enrolled. At baseline and after a 3-week probiotic oral suspension (POS) intake, all subjects underwent evaluation of body composition by anthropometry and dual X-ray absorptiometry, and psychological profile assessment by self-report questionnaires (i.e. EDI-2, SCL90R and BUT). Statistical analysis was carried out using paired t test or a non-parametric Wilcoxon test to evaluate differences between baseline and after POS intake, one-way ANOVA to compare all three groups and, where applicable, Chi square or t test were used to assess symptoms. Results Of the 48 women that concluded the study, 24% were NWO, 26% were NWL and 50% were PreOB/OB. Significant differences in body composition were highlighted among groups both at baseline and after a POS (p
- Published
- 2017
- Full Text
- View/download PDF
6. Pharmacologic and genetic inhibition of cholesterol esterification enzymes reduces tumour burden: A systematic review and meta-analysis of preclinical models
- Author
-
Marc Poirot, Ruoying Wu, Thomas A. Hughes, Xinyu Chen, Michael A. Zulyniak, Xinyu Luo, Philip Chalmers, Alex Websdale, Mengfan Xu, Giorgia Cioccoloni, James L. Thorne, Rufaro Mwarzi, Yi Kiew, Hanne Roberg-Larsen, University of Leeds, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Oslo (UiO), Poirot, Marc, and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Coenzyme A ,[SDV]Life Sciences [q-bio] ,Organic Anion Transporters ,Antineoplastic Agents ,Pharmacology ,Biochemistry ,Metastasis ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Lipid droplet ,medicine ,Animals ,Humans ,Urea ,030304 developmental biology ,chemistry.chemical_classification ,0303 health sciences ,Clinical Trials as Topic ,Esterification ,Chemistry ,Cholesterol ,Anticholesteremic Agents ,Cancer ,medicine.disease ,Xenograft Model Antitumor Assays ,3. Good health ,Tumor Burden ,[SDV] Life Sciences [q-bio] ,Enzyme ,Apoptosis ,030220 oncology & carcinogenesis ,Cholesteryl ester - Abstract
International audience; Cholesterol esterification proteins Sterol-O acyltransferases (SOAT) 1 and 2 are emerging prognostic markers in many cancers. These enzymes utilise fatty acids conjugated to coenzyme A to esterify cholesterol. Cholesterol esterification is tightly regulated and enables formation of lipid droplets that act as storage organelles for lipid soluble vitamins and minerals, and as cholesterol reservoirs. In cancer, this provides rapid access to cholesterol to maintain continual synthesis of the plasma membrane. In this systematic review and meta-analysis, we summarise the current depth of understanding of the role of this metabolic pathway in pan-cancer development. A systematic search of PubMed, Scopus, Web of Science, and Cochrane Library for preclinical studies identified eight studies where cholesteryl ester concentrations were compared between tumour and adjacent-normal tissue, and 24 studies where cholesterol esterification was blocked by pharmacological or genetic approaches. Tumour tissue had a significantly greater concentration of cholesteryl esters than non-tumour tissue (p < 0.0001). Pharmacological or genetic inhibition of SOAT was associated with significantly smaller tumours of all types (p ≤ 0.002). SOAT inhibition increased tumour apoptosis (p = 0.007), CD8 + lymphocyte infiltration and cytotoxicity (p ≤ 0.05), and reduced proliferation (p = 0.0003) and metastasis (p < 0.0001). Significant risk of publication bias was found and may have contributed to a 32% overestimation of the meta-analysed effect size. Avasimibe, the most frequently used SOAT inhibitor, was effective at doses equivalent to those previously reported to be safe and tolerable in humans. This work indicates that SOAT inhibition should be explored in clinical trials as an adjunct to existing anti-neoplastic agents.
- Published
- 2021
7. A Hazelnut-Enriched Diet Modulates Oxidative Stress and Inflammation Gene Expression without Weight Gain
- Author
-
Ludovico Abenavoli, Andrea Cammarano, Santo Gratteri, Giorgia Cioccoloni, Marco Marchetti, Iraj Alipourfard, Vincenzo Aiello, Sergio Bernardini, Laura Di Renzo, and Ida Ceravolo
- Subjects
0301 basic medicine ,Aging ,Antioxidant ,Article Subject ,medicine.medical_treatment ,Gene Expression ,Inflammation ,Pilot Projects ,030204 cardiovascular system & hematology ,Biology ,medicine.disease_cause ,Settore BIO/09 ,Biochemistry ,Calcitriol receptor ,Corylus ,Healthy Volunteers ,Humans ,Middle Aged ,Obesity ,Oxidative Stress ,Prospective Studies ,03 medical and health sciences ,0302 clinical medicine ,Nutraceutical ,medicine ,Food science ,lcsh:QH573-671 ,lcsh:Cytology ,Settore BIO/12 ,Cell Biology ,General Medicine ,medicine.disease ,030104 developmental biology ,Methylenetetrahydrofolate reductase ,biology.protein ,Clinical Study ,medicine.symptom ,Weight gain ,Oxidative stress - Abstract
Introduction. Inflammation is associated with obesity condition and plays a pivotal role in the onset and progression of many chronic diseases. Among several nutraceutical foods, hazelnuts (Corylus avellana L.) are considered an excellent anti-inflammatory and hypolipidemic food being the second richest source of monounsaturated fatty acids among nuts and because they are rich in vitamins, minerals, and phenolic compounds. Materials and Methods. A prospective pilot clinical trial on 24 healthy volunteers who consumed daily, as a snack, 40 g of hazelnuts (261.99 kcal/1096.17 kJ) for six weeks was conducted. Anthropometric measurements, body composition analysis, and nutrigenomic analysis on 12 anti-inflammatory and antioxidant genes were evaluated at baseline (T0) and after hazelnut intervention (T1). Results. No significant changes were detected on body composition analysis after hazelnut consumption. Conversely, significant upregulation was detected for SOD1 (2−ΔΔCt=2.42), CAT (2−ΔΔCt=2.41), MIF (2−ΔΔCt=4.12), PPARγ (2−ΔΔCt=5.89), VDR (2−ΔΔCt=3.61), MTHFR (2−ΔΔCt=2.40), and ACE (2−ΔΔCt=2.16) at the end of the study. Conclusions. According to emerging evidences, hazelnut consumption does not lead to weight gain probably due to the improvement of the body’s antioxidant capacity by the upregulation of genes implied in oxidant reactions and inflammation.
- Published
- 2019
8. Single nucleotide polymorphism A-511 G of IL-1 gene modifies anthropometric and physiological parameters of athletes
- Author
-
Fabrizio Spataro, Akbar Abbasi, A. Khamoushi, A De Lorenzo, L Di Renzo, Iraj Alipourfard, and Giorgia Cioccoloni
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Genotyping ,medicine.medical_treatment ,Single-nucleotide polymorphism ,Biology ,Settore MED/49 ,03 medical and health sciences ,0302 clinical medicine ,Anthropometric ,IL-1 ,Physiological parameters ,Internal medicine ,Genetics ,medicine ,SNP ,Allele ,Gene ,Genetics (clinical) ,Athletes ,Leptin ,Wild type ,biology.organism_classification ,030104 developmental biology ,Cytokine ,Endocrinology ,030220 oncology & carcinogenesis - Abstract
Interleukin-1β is one of pro-inflammatory responses and plays an important role in cell proliferation, differentiation, and apoptosis . The gene of this cytokine is highly polymorphic, one of which is located on 5´flanking region at position −511 (rs16944, A-511 G). This allele encodes IL-1β protein with less activity in comparison with wild type. In this research, 40 subjects of professional athletes in futsal and volleyball fields have been studied in their anthropometric and physiological indexes and also IL-1β genetic polymorphisms. Our results show that in subjects carrying IL-1β A (−) SNP or wild type allele, the weight, body fat and some other physiological indexes have been increased. This might have relation with elevated plasma level of leptin which is conducted by IL-1β A (−) allele. These findings suggest a remarkable relation between genetic polymorphisms of IL-1β gene and physical potential of athletes.
- Published
- 2019
9. Influence of FTO rs9939609 and Mediterranean diet on body composition and weight loss: a randomized clinical trial
- Author
-
Alessandra Moia, Ludovico Abenavoli, Laura Di Renzo, Giorgia Cioccoloni, Antonino De Lorenzo, Simone Falco, and Paola Sinibaldi Salimei
- Subjects
Male ,Mediterranean diet ,Body water ,Alpha-Ketoglutarate-Dependent Dioxygenase FTO ,Physiology ,lcsh:Medicine ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Diet, Mediterranean ,Polymorphism, Single Nucleotide ,Body composition ,General Biochemistry, Genetics and Molecular Biology ,Nutrigenetics ,Body Mass Index ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Gene Frequency ,Randomized controlled trial ,Weight loss ,law ,Weight Loss ,medicine ,Humans ,Trial registration ,business.industry ,Research ,lcsh:R ,Total body ,General Medicine ,Middle Aged ,medicine.disease ,Obesity ,Italy ,Female ,medicine.symptom ,business ,FTO - Abstract
Background The Mediterranean diet (MeD) plays a key role in the prevention of obesity. Among the genes involved in obesity, the Fat mass and obesity-associated gene (FTO) is one of the most known, but its interaction with MeD remained uncertain so far. Methods We carried out a study on a sample of 188 Italian subjects, analyzing their FTO rs9939609 alleles, and the difference in body composition between the baseline and a 4-weeks nutritional intervention. The sample was divided into two groups: the control group of 49 subjects, and the MeD group of 139 subjects. Results We found significant relations between MeD and both variation of total body fat (ΔTBFat) (p = 0.00) and gynoid body fat (p = 0.04). ∆TBFat (kg) demonstrated to have a significant relation with the interaction diet-gene (p = 0.04), whereas FTO was associated with the variation of total body water (p = 0.02). Conclusions MeD demonstrated to be a good nutritional treatment to reduce the body fat mass, whereas data about FTO remain uncertain. Confirming or rejecting the hypothesis of FTO and its influence on body tissues during nutritional treatments is fundamental to decide whether its effect has to be taken into consideration during both development of dietetic plans and patients monitoring. Trial Registration ClinicalTrials.gov Id: NCT01890070. Registered 01 July 2013, https://clinicaltrials.gov/ct2/show/NCT01890070
- Published
- 2018
10. Antioxidant Effects of a Hydroxytyrosol-Based Pharmaceutical Formulation on Body Composition, Metabolic State, and Gene Expression: A Randomized Double-Blinded, Placebo-Controlled Crossover Trial
- Author
-
Renata Costa de Miranda, Domenico Trombetta, Antonino De Lorenzo, Giorgia Cioccoloni, Paola Gualtieri, Carmela Colica, Antonella Smeriglio, Laura Di Renzo, Sergio Bernardini, and Paola Sinibaldi Salimei
- Subjects
0301 basic medicine ,Male ,Aging ,Antioxidant ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Pharmacology ,medicine.disease_cause ,Biochemistry ,Biochemistry, Aging, Cell Biology ,Antioxidants ,Placebos ,chemistry.chemical_compound ,Eating ,0302 clinical medicine ,Settore MED/49 - Scienze Tecniche Dietetiche Applicate ,Endothelial dysfunction ,Unsaturated ,biology ,lcsh:Cytology ,Chemistry ,Fatty Acids ,General Medicine ,Middle Aged ,Phenylethyl Alcohol ,Malondialdehyde ,Body Composition ,Fatty Acids, Unsaturated ,Female ,Adult ,Article Subject ,Drug Compounding ,Placebo ,Superoxide dismutase ,03 medical and health sciences ,Young Adult ,Double-Blind Method ,medicine ,Humans ,lcsh:QH573-671 ,030109 nutrition & dietetics ,Erythrocyte Membrane ,Cell Biology ,medicine.disease ,Crossover study ,Gene Expression Regulation ,biology.protein ,Clinical Study ,Hydroxytyrosol ,Oxidative stress - Abstract
Hydroxytyrosol (HT) plays a significant role in cardiovascular disease (CVD) protection, and its metabolites are able to protect from the endothelial dysfunction commonly present in atherosclerosis. This randomized double-blinded, placebo-controlled crossover trial determined the effect in healthy volunteers of two gastroresistant capsules containing 15 mg/day of HT, for a 3-week period (HTT). Evaluation of nutritional status, serum metabolites, oxidative stress biomarkers, and gene expression of 9 genes related to oxidative stress, inflammation, and CVDs was performed. Oxidation biomarkers like thiol group (p=0.001), total antioxidant status (TAS) (p=0.001), superoxide dismutase 1 (SOD1) (2−ΔΔCt = 3.7), and plasma concentration of HT (2.83μg·mL−1) were significantly increased, while nitrite (p=0.001), nitrate (p=0.001), and malondialdehyde (MDA) (p=0.02) were drastically reduced after HTT. A significant reduction of body fat mass percentage (p=0.01), suprailiac skinfold (p=0.01), and weight (p=0.04; Δ% = −0.46%) was observed after HTT. This study shows that regular intake of 15 mg/day of HT changed body composition parameters and modulated the antioxidant profile and the expression of inflammation and oxidative stress-related genes. However, it is advisable to personalize HT doses in order to exert its health benefits in CVD prevention and protection of LDL-C particles from oxidative damage. This trial is registered with ClinicalTrials.govNCT01890070.
- Published
- 2017
11. Antioxidant effects of a hydroxytyrosol-based pharmaceutical formulation on body composition, metabolic state, and gene expression: a randomized double-blinded, placebo-controlled crossover trial
- Author
-
Trombetta, Domenico, Laura Di Renzo, Smeriglio, Antonella, Sergio, Bernardini, Giorgia, Cioccoloni, Renata, Miranda, Paola, Gualtieri, and Antonino De Lorenzo
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.